Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Dimensions Stories

2011-11-07 17:32:00

KIRKLAND, Wash., Nov. 7, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that an update to its landmark TITAN clinical trial will be given as part of the 23rd annual Transcathether Cardiovascular Therapeutics (TCT) Conference being held at the Moscone Center in San Francisco. Steven L. Goldberg, M.D., the Company's Chief Clinical Officer will deliver a presentation entitled, Cardiac Dimensions CARILLON XE2: Foundational Results and Design Iteration Toward...

2011-09-29 16:47:00

KIRKLAND, Wash., Sept. 29, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON® Mitral Contour System(TM), a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR). Receipt of the CE Mark enables Cardiac Dimensions to initiate a commercial launch of the enhanced device in Europe, which the...

2011-05-04 05:00:00

KIRKLAND, Wash., May 4, 2011 /PRNewswire/ -- Cardiac Dimensions®, Inc. announced today the initiation of two new clinical studies using the CARILLON® Mitral Contour System(TM), an investigational device for percutaneous treatment of Functional Mitral Regurgitation (FMR). The CARILLON system is a minimally invasive device designed to repair the heart's mitral valve and reduce FMR, a disorder that affects most of the estimated 5 million people in the U.S....

2010-08-18 05:00:00

KIRKLAND, Wash., Aug. 18 /PRNewswire/ -- Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN(TM) trial of the Company's CARILLON® Mitral Contour System will be presented at the European Society of Cardiology 2010 Congress (ESC) on August 29, 2010 in Stockholm. Professor Dr. Uta Hoppe of...